Statement: A patient with a Histologically confirmed breast cancer would be accepted for the primary trial and the secondary trial.
Primary_evidence: Inclusion Criteria:   Histologically or cytologically confirmed breast carcinoma.   Early stage breast cancer (stage 1, 2, 3).   No evidence of disease outside the breast or chest wall, except ipsilateral axillary lymph nodes.   18 years of age or older.   Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Exclusion Criteria:   Prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancer.   Major surgery within 28 days of study entry.   Evidence of central nervous system (CNS) metastases.   Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Secondary_evidence: Inclusion Criteria:   Patients with cytologically confirmed breast cancer with biopsy showing invasive or non-invasive (DCIS) at least 1.0 cm greatest diameter on imaging   Surgical patients undergoing lumpectomy, subtotal or total mastectomy   18 years of age or greater   female   available tissue blocks from diagnostic biopsy   negative pregnancy test, medical history of surgical sterilization, or 1 year post menopausal   must be willing to forego surgery for minimum of 5 days   ability and willingness to sign written consent   if hypertensive, on stable dose of medication at least 30 days   if diabetic, well controlled (HbA1C < 8.5 within past 60 days or documented FPG < 140 mg/dl for 3 consecutive days   ECOG status < 2 or Karnofsky of 60% or greater Exclusion Criteria:   previous or current malignancy, excluding non-melanomic skin cancer   evidence of distant metastatic disease   history of chemotherapy, biologic or radiotherapy with 6 months of biopsy   usage of herbal supplements or alternative medications not approved by the FDA within 1 week of starting study drug. LEAG or related ginseng products, and combination products containing ginseng, should be discontinued within 6 weeks of starting study drug   history of allergic reactions attributed to compounds of similar chemical or biologic composition to LEAG   history of chronic inflammatory process, including, but not limited to, rheumatoid arthritis and lupus. This includes patients on concurrent systemic steroids or anti-inflammatory medications   active bleeding or a pathological condition that carries a high risk of bleeding   any swallowing dysfunction   uncontrolled intercurrent illness   poorly controlled diabetes (control indicated with HbA1c < 8.5 within past 60 days or documented fasting blood glucose < 140 mg/dl for three consecutive days)   known diabetics who have experienced episodes of symptomatic hypoglycemia in the last 6 months are also considered poorly controlled and will be excluded from study participation.   uncontrolled hypertension (SBP > 140 mmHg or DBP > 90 mmHG)   pregnant or breast feeding women Women must be willing to use birth control throughout study duration.   current investigational medications or treatment with an investigational agent within 6 weeks prior to biopsy   current coumadin therapy or who have been treated with coumadin within the 2 weeks prior to biopsy   current monoamine oxidase inhibitors treatment